Biogen (BIIB)

286.00 -0.14 (0.05%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (1/29/20 *Est.)
- Spin-Off (3/31/17 *Est)

Latest Headlines

Biogen (BIIB) PT Raised to $270 at Morgan Stanley January 17, 2020 8:31 AM - StreetInsider Biogen (BIIB) February option implied volatility bid January 16, 2020 2:36 PM - StreetInsider Biogen (BIIB) Tests Low, Shares Down 2.4% January 16, 2020 2:08 PM - StreetInsider Biogen (BIIB) February option implied volatility bid January 16, 2020 5:33 AM - StreetInsider Biogen (BIIB) option volume increases on price movement January 15, 2020 5:33 AM - StreetInsider Biogen (BIIB) option prices and share price moving into events January 14, 2020 1:31 PM - StreetInsider Biogen (BIIB) bid ask spreads widen as shares rally January 14, 2020 1:24 PM - StreetInsider Biogen (BIIB) spikes higher; pares gains; Last up 1% January 14, 2020 1:24 PM - StreetInsider Biogen (BIIB) February 295 calls active January 14, 2020 1:09 PM - StreetInsider Biogen (BIIB) call put ratio 4.5 calls to 1 put with focus on February 295 calls January 14, 2020 12:40 PM - StreetInsider Biogen (BIIB) option implied volatility at lower end of range January 14, 2020 4:23 AM - StreetInsider Biogen (BIIB) February option implied volatility flat at 39 as shares sell off 1% January 13, 2020 2:53 PM - StreetInsider Biogen (BIIB) to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc. (PFE) January 13, 2020 7:31 AM - StreetInsider Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. January 13, 2020 7:31 AM - StreetInsider Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. January 13, 2020 7:30 AM - Globe NewsWire CAMP4 Announces Collaboration to Discover Novel Targets to Address Neurodegenerative and Neurological Diseases January 10, 2020 7:00 AM - BizWire Banner Life Sciences Gets Favorable Ruling Vs Biogen (BIIB) - Bloomberg January 9, 2020 12:23 PM - StreetInsider Biogen (BIIB) IV bid into JPMorgan 38th Annual Healthcare Conference January 8, 2020 10:18 AM - StreetInsider Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy January 8, 2020 7:30 AM - PR NewsWire Form 4 BIOGEN INC. For: Jan 02 Filed by: CAPELLO JEFFREY D January 6, 2020 4:14 PM - SEC Filing Biogen (BIIB) Increased Pricing on Jan 1- Piper Jaffray January 2, 2020 7:04 AM - StreetInsider More drugmakers hike U.S. prices as new year begins January 1, 2020 11:20 AM - StreetInsider Biogen (BIIB) option implied volatility at low end of range December 20, 2019 10:41 AM - StreetInsider Biogen (BIIB) Announces $5B Buyback December 19, 2019 4:21 PM - StreetInsider Form 8-K BIOGEN INC. For: Dec 19 December 19, 2019 4:16 PM - SEC Filing Catalyst Biosciences (CBIO) announces pact with Biogen (BIIB) for development and commercialization of pegylated CB 2782 for potential treatment of GA associated dry AMD December 19, 2019 8:05 AM - StreetInsider Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration December 19, 2019 8:00 AM - Globe NewsWire Ionis Pharmaceuticals (IONS) licenses investigational Alzheimer's therapy to Biogen (BIIB) December 19, 2019 7:08 AM - StreetInsider Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug December 13, 2019 3:30 PM - StreetInsider Biogen (BIIB) Phase 2 PASSPORT study of gosuranemab for PSP misses primary endpoint December 13, 2019 7:31 AM - StreetInsider Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy December 13, 2019 7:31 AM - StreetInsider Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy December 13, 2019 7:30 AM - Globe NewsWire UPDATE: Credit Suisse Upgrades Biogen (BIIB) to Neutral December 13, 2019 4:55 AM - StreetInsider Form 4 BIOGEN INC. For: Dec 03 Filed by: Kramer Robin December 5, 2019 4:25 PM - SEC Filing Biogen (BIIB) Hits Session High, Up 6% December 5, 2019 12:09 PM - StreetInsider Biogen (BIIB) Resumes Trading, Now Down Over 3% December 5, 2019 11:35 AM - StreetInsider Biogen (BIIB) to Resume Trading at 11:35 am December 5, 2019 11:14 AM - StreetInsider Biogen (BIIB) Releases Slides for Aducanumab Phase 3 Studies Presentation December 5, 2019 11:12 AM - StreetInsider Biogen (BIIB) Trading Halt Tied to CTAD Presentation for Alzheimer's Drug December 5, 2019 10:58 AM - StreetInsider Biogen (BIIB) Halted, News Pending December 5, 2019 10:55 AM - StreetInsider Biogen (BIIB) IV elevated into conference call December 5, 2019 10:19 AM - StreetInsider Biogen (BIIB) option implied volatility elevated into data December 5, 2019 9:31 AM - StreetInsider Biogen (BIIB) IV bid elevated into Aducanumab conference call December 5, 2019 5:20 AM - StreetInsider Options expected to have increasing volume: BIIB RH KR DG TIF December 5, 2019 5:03 AM - StreetInsider Biogen (BIIB) option implied volatility elevated into treatment data December 4, 2019 10:26 AM - StreetInsider Biogen (BIIB) option implied volatility into presentation December 4, 2019 5:28 AM - StreetInsider Form 4 BIOGEN INC. For: Dec 01 Filed by: Guindo Chirfi December 3, 2019 6:00 PM - SEC Filing Form 4 BIOGEN INC. For: Dec 02 Filed by: Posner Brian S December 3, 2019 5:58 PM - SEC Filing Biogen (BIIB) call put ratio 1 call to 2.4 puts with focus on December weekly puts into data December 3, 2019 9:50 AM - StreetInsider Biogen (BIIB) Reports Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) December 3, 2019 7:32 AM - StreetInsider Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) December 3, 2019 7:31 AM - StreetInsider Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) December 3, 2019 7:30 AM - Globe NewsWire Biogen (BIIB) option implied volatility increases into data December 3, 2019 5:55 AM - StreetInsider Biogen (BIIB) Set to Open Lower Following Downgrade December 2, 2019 6:51 AM - StreetInsider Biogen (BIIB) option implied volatility bid into Alzheimer’s treatment data December 2, 2019 5:33 AM - StreetInsider Baird Downgrades Biogen (BIIB) to Underperform on Alzheimer's Hype, 'CTAP Looks Ripe for Downside' December 2, 2019 4:30 AM - StreetInsider Biogen (BIIB) option implied volatility stays low as shares rally 2.3% November 25, 2019 10:51 AM - StreetInsider Biogen (BIIB) Ticks Higher Following CNBC Mention November 25, 2019 10:44 AM - StreetInsider Biogen (BIIB) Settles Patent Fight with Glenmark Over Tecfidera - Bloomberg November 22, 2019 12:34 PM - StreetInsider Biogen (BIIB) december 330 call IV 57 up 3.7%, 20 strikes +20 contracts November 22, 2019 12:31 PM - StreetInsider Biogen (BIIB) Trades at High, Up 3.2% November 22, 2019 12:23 PM - StreetInsider Biogen (BIIB) Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY Compared to TECFIDERA November 22, 2019 7:31 AM - StreetInsider Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) November 22, 2019 7:30 AM - Globe NewsWire Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) November 22, 2019 7:30 AM - StreetInsider Biogen (BIIB) Reports Complete Enrollment of Global Phase 3 Gene Therapy Study for Inherited Retinal Disorder November 21, 2019 7:37 AM - StreetInsider Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder November 21, 2019 7:30 AM - Globe NewsWire Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder November 21, 2019 7:30 AM - StreetInsider Biogen (BIIB) New 'Mystery' Candidate BIIB101 Moves Into Clinic - RBC November 18, 2019 12:49 PM - StreetInsider Biogen (BIIB) Hits Low, Down 2.65% November 14, 2019 10:15 AM - StreetInsider Biogen (BIIB) Falls to Low, Down 2.4% November 13, 2019 9:53 AM - StreetInsider Alkermes (ALKS) Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY November 12, 2019 7:06 AM - StreetInsider Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™ November 12, 2019 7:00 AM - PR NewsWire UPDATE: SunTrust Starts Biogen (BIIB) at Buy November 12, 2019 4:31 AM - StreetInsider Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates November 6, 2019 7:46 AM - BizWire Biogen (BIIB) announced new proposed transaction with Samsung Bioepis November 6, 2019 7:40 AM - StreetInsider Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis November 6, 2019 7:30 AM - Globe NewsWire Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis November 6, 2019 7:30 AM - StreetInsider Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 November 4, 2019 4:30 PM - Globe NewsWire Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019 November 4, 2019 4:30 PM - StreetInsider UPDATE: CORRECTION: Standpoint Research Downgrades Biogen (BIIB) to Hold from Buy November 1, 2019 1:01 PM - StreetInsider Pre-Open 10/30: (BGFV) (GDOT) (GEL) Higher (CYCN) (QUAD) (AMAG) Lower (more...) October 30, 2019 9:30 AM - StreetInsider Biogen (BIIB) and Alkermes ( ALKS) set to open higher after FDA approves VUMERITY for MS October 30, 2019 8:13 AM - StreetInsider Biogen (BIIB), Alkermes (ALKS) Report FDA Approval of VUMERITY (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:40 AM - StreetInsider Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:31 AM - StreetInsider Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:30 AM - Globe NewsWire Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis October 30, 2019 7:30 AM - PR NewsWire Bernstein Upgrades Biogen (BIIB) to Outperform, Boosts PT on Positive Aducanumab Risk-Reward October 29, 2019 4:28 PM - StreetInsider Biogen (BIIB) on Watch on Cautious Article October 28, 2019 11:14 AM - StreetInsider Biogen's secret campaign to bring its Alzheimer's drug back from the ashes October 25, 2019 7:08 AM - StreetInsider Stocks with Implied Volatility Movement October 25, 2019 4:23 AM - StreetInsider Biogen (BIIB) PT Raised to $290 at Goldman Sachs October 23, 2019 8:58 AM - StreetInsider Biogen (BIIB) PT Raised to $235 at BofA/Merrill Lynch October 23, 2019 8:54 AM - StreetInsider Biogen (BIIB) PT Raised to $335 at H.C. Wainwright October 23, 2019 7:45 AM - StreetInsider Biogen (BIIB) PT Raised to $300 at Cantor Fitzgerald on 30% Aducanumab POS October 23, 2019 7:31 AM - StreetInsider Biogen (BIIB) PT Raised to $325 at Cowen October 23, 2019 7:31 AM - StreetInsider Biogen (BIIB) PT Raised to $262 at Morgan Stanley October 23, 2019 7:11 AM - StreetInsider SVB Leerink Upgrades Biogen (BIIB) to Outperform October 23, 2019 7:11 AM - StreetInsider Biogen (BIIB) 30% Move is Justified - Nomura/Instinet October 23, 2019 6:39 AM - StreetInsider Biogen (BIIB) PT Raised to $260 at Credit Suisse October 23, 2019 6:36 AM - StreetInsider Biogen (BIIB) PT Raised to $315 at Citi October 23, 2019 6:13 AM - StreetInsider UPDATE: Guggenheim Upgrades Biogen (BIIB) to Buy October 23, 2019 6:10 AM - StreetInsider Biogen (BIIB) PT Raised to $305 at Canaccord Genuity October 23, 2019 5:14 AM - StreetInsider Biogen (BIIB) PT Raised to $297 at BMO Capital October 23, 2019 4:44 AM - StreetInsider Increasing unusual put option volume: GNW GDI BIIB GOSS CATM CTVA ODP GME October 23, 2019 4:36 AM - StreetInsider Stocks with Implied Volatility Movement October 23, 2019 4:24 AM - StreetInsider Biogen, Eisai revive plans for Alzheimer's drug, surprising market October 22, 2019 5:08 PM - StreetInsider Form 10-Q BIOGEN INC. For: Sep 30 October 22, 2019 4:14 PM - SEC Filing Biogen (BIIB) ALZ Drug Has 0% Chance of Winning Approval: Raymond James - Bloomberg October 22, 2019 3:50 PM - StreetInsider Biogen (BIIB) PT Raised to $310 at Jefferies October 22, 2019 1:45 PM - StreetInsider Biogen (BIIB) PT Raised to $249 at Wedbush October 22, 2019 12:44 PM - StreetInsider Biogen (BIIB) PT Raised to $296 at Stifel October 22, 2019 12:11 PM - StreetInsider Biogen (BIIB) PT Raised to $334 at Oppenheimer Amid Aducanuma News October 22, 2019 11:53 AM - StreetInsider Increasing unusual option volume: HHC GOSS HOG BIIB SSYS FBHS PBF TGP HCA LLNW October 22, 2019 11:18 AM - StreetInsider Increasing unusual put option volume: GOSS CATM BIIB HCA WEC SSYS TRV WPM HOG October 22, 2019 9:52 AM - StreetInsider Pre-Open 10/22: (BIIB) (STMP) (GNC) Higher (TTS) (TEUM) (HHC) Lower (more...) October 22, 2019 9:30 AM - StreetInsider Wall Street slips after rejection of Brexit timetable October 22, 2019 7:50 AM - StreetInsider Biogen (BIIB) News 'Somewhat Astonishing', Shares Could Trade Back Toward Low-$300s - RBC October 22, 2019 7:32 AM - StreetInsider Form 8-K BIOGEN INC. For: Oct 22 October 22, 2019 7:09 AM - SEC Filing Biogen (BIIB) Tops Q3 EPS by 90c October 22, 2019 6:53 AM - StreetInsider Biogen (BIIB) Surges 18.5% Pre-Market After Announcing Plans to Pursue Regulatory Approval for Aducanumab in Alzheimer’s Disease October 22, 2019 6:41 AM - StreetInsider Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA October 22, 2019 6:33 AM - StreetInsider Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies October 22, 2019 6:31 AM - StreetInsider Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies October 22, 2019 6:30 AM - Globe NewsWire Biogen (BIIB) IV flat into EPS and outlook October 21, 2019 10:18 AM - StreetInsider Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week October 21, 2019 7:31 AM - StreetInsider Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week October 21, 2019 7:30 AM - Globe NewsWire Full Article List